Abstract Number: 1059 • 2016 ACR/ARHP Annual Meeting
Quality of Life in Patients with Antiphospholipid Syndrome Is Related to Disease Burden and Anticoagulant Therapy
Background/Purpose: Few studies have reported impaired health related quality of life (HRQoL) in patients with primary antiphospholipid syndrome (APS); however the causes of this outcome…Abstract Number: 1060 • 2016 ACR/ARHP Annual Meeting
Antiphospholipid Antibodies and Related Clinical Events Following Infection in Children: A Systematic Review of Case Reports
Background/Purpose: A systematic review of case reports to summarize existing evidence in the literature regarding the association of APS and infection during childhood. Our aims…Abstract Number: 1061 • 2016 ACR/ARHP Annual Meeting
Identifying Clinical and Epidemiological Risk Factors Associated with Thrombosis and Pregnancy Morbidity in a Large Cohort of Chinese APS Patients
Background/Purpose: It is well known that anti-phospholipid antibodies (aPL) are associated with an increased risk of arterial and venous thrombosis and pregnancy loss/morbidity. However, assessment…Abstract Number: 1062 • 2016 ACR/ARHP Annual Meeting
Non-Conventional Antiphospholipid Antibodies in Patients with Clinical Obstetrical APS: Prevalence and Pregnancies Treatment Efficacy
Background/Purpose: To describe the prevalence of non-conventional APL in patients with obstetrical APS pregnancy adverse outcome without conventional APL and the impact of treatment on…Abstract Number: 1063 • 2016 ACR/ARHP Annual Meeting
A Systematic Review of Direct Oral Anticoagulant Use in Antiphospholipid Syndrome
Background/Purpose: Oral direct oral anticoagulants (DOACs) are approved for the treatment of venous thrombosis and the prevention of venous/arterial thrombosis. There is growing information from…Abstract Number: 1064 • 2016 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome Alliance for Clinical Trials & International Networking Registry Analysis: Direct Oral Anticoagulant Use Among Antiphospholipid Syndrome Patients
Background/Purpose: Direct oral anticoagulants (DOACs) are approved for the treatment of venous, and prevention of venous/arterial thrombosis. There have been case reports/ series where DOACs…Abstract Number: 1065 • 2016 ACR/ARHP Annual Meeting
A Practical Application of Antiphospholipid Antibodies Profiles in the Diagnosis and Managements of Antiphospholipid Syndrome: The Modified Antiphospholipid Score
Background/Purpose: The clinical scoring systems to quantify the probability for the diagnosis of antiphospholipid syndrome (APS) or future thrombosis, have been proposed as to reflect…Abstract Number: 1066 • 2016 ACR/ARHP Annual Meeting
History of Lupus Nephritis Is an Independent Risk Factor for Thrombosis in Systemic Lupus Erythematosus Patients with Antiphospholipid Antibodies
Background/Purpose: Few studies have analyzed the risk factors for thrombosis in Systemic Lupus Erythematosus (SLE) patients with antiphospholipid antibodies (aPL) and most had small sample…Abstract Number: 1067 • 2016 ACR/ARHP Annual Meeting
History of Thrombocytopenia Is Associated with Lower Prevalence of Thrombotic Events in Systemic Lupus Erythematosus Patients with Antiphospholipid Antibodies
Background/Purpose: Thrombocytopenia is a common feature of both systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) and in the former most frequently results from antiplatelet…Abstract Number: 1068 • 2016 ACR/ARHP Annual Meeting
Recurrence of Thrombosis Despite Negativization of Antiphospholipid Antibodies in Primary Antiphospholipid Syndrome. a Follow-up to 5 Years
Background/Purpose: In some antiphospholipid syndrome (APS) patients, the antiphospholipid antibodies (aPL) becomes persistently negative. Discontinuation of anticoagulation has been proposed, however the long term follow-up…Abstract Number: 1069 • 2016 ACR/ARHP Annual Meeting
The Predictive Value of Acl and Anti-β2GPI in Patients with Acute Deep Vein Thrombosis
Background/Purpose: Acute deep vein thrombosis (DVT) is generally treated with anticoagulants for 3 to 6 months. Antiphospholipid syndrome (APS) is an important cause of DVT.…Abstract Number: 1070 • 2016 ACR/ARHP Annual Meeting
Performance and External Validation of the Damage Index in Antiphospholipid Syndrome in Primary and Secondary APS Patients
Background/Purpose: In APS, irreversible organ damage may result of disease activity, medications, or comorbid illnesses. To assess it, different methods have been used including the…Abstract Number: 1071 • 2016 ACR/ARHP Annual Meeting
Anti-β2GP-I-Domain 3 and Aps/PT-IgG Antibodies Identify Primary APS Patients with Both Thrombotic and Hematological Manifestations
Background/Purpose: Thrombocytopenia and hemolytic anemia (HA) are considered non-criteria clinical manifestations by the Sydney revised criteria for APS. These features can precede, follow a thrombotic…Abstract Number: 1072 • 2016 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome Alliance for Clinical Trials & International Networking Registry Analysis: Cardiovascular Risk Factors Among Different Groups of Antiphospholipid Antibody-Positive Patients
Background/Purpose: Traditional cardiovascular disease (CVD) risk factors increase the risk of thrombotic clinical manifestations in antiphospholipid antibody (aPL)-positive patients. The prevalence of CVD risk factors…Abstract Number: 1073 • 2016 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome Alliance for Clinical Trials & International Networking (APS ACTION) Clinical Database and Repository Analysis: The Comparison of Real World and Core Laboratory Antiphospholipid Antibody ELISA Results
Background/Purpose: The APS ACTION International Clinical Database and Repository (“Registry”) was created to study the natural course of disease over 10 years in persistently aPL-positive…
ACR Meeting Abstracts